Low dose exemestane vs low dose tamoxifen for breast cancer prevention
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares two low-dose medications, exemestane and tamoxifen, to see which is better at preventing breast cancer in postmenopausal women who have a higher risk. You would take one of these pills daily for a few years, and the study will check how well it works and what side effects occur.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have gone through menopause (no periods for 12 months or have had your ovaries removed).
- You have a high risk of breast cancer due to one of these: recent non-invasive breast cancer (DCIS), a prior high-risk breast lesion (like ADH or LCIS), a risk score of 3% or more over 5 years, carrying a CHEK2 or ATM gene change, or having chest radiation before age 30.
- You are able to swallow pills and are in generally good health (able to do daily activities).
- You have had a mammogram and a gynecological exam within the last 6 months, and a bone density scan within the last year.
- You have not used any antiestrogen medications (like tamoxifen or raloxifene) in the past year and no hormone replacement therapy in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two low-dose hormone blockers (exemestane and tamoxifen) to see which one is better at preventing breast cancer in postmenopausal women who are at high risk. You will have a 50% chance of getting either drug, and the study will follow you for several years to compare their effectiveness and side effects.
This trial compares a new medicine, elacestrant, to the usual hormone therapy for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a high chance of it coming back. The goal is to see if elacestrant works better at preventing the cancer from returning.
This trial tests whether adjusting the dose of tamoxifen based on your body's processing can improve treatment for hormone-sensitive breast cancer. It aims to find the best dose for you while keeping side effects manageable.
This study looks at whether taking hormone-blocking pills for longer than 5 years can help lower the risk of breast cancer returning. It is for people who had lymph node involvement and have already completed their initial 5-year treatment without the cancer coming back.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.